209 related articles for article (PubMed ID: 24756365)
1. Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies.
Chinn DC; Holland WS; Mack PC
J Cancer Res Clin Oncol; 2014 Jul; 140(7):1137-49. PubMed ID: 24756365
[TBL] [Abstract][Full Text] [Related]
2. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.
Shimomura T; Hasako S; Nakatsuru Y; Mita T; Ichikawa K; Kodera T; Sakai T; Nambu T; Miyamoto M; Takahashi I; Miki S; Kawanishi N; Ohkubo M; Kotani H; Iwasawa Y
Mol Cancer Ther; 2010 Jan; 9(1):157-66. PubMed ID: 20053775
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors.
Amin M; Minton SE; LoRusso PM; Krishnamurthi SS; Pickett CA; Lunceford J; Hille D; Mauro D; Stein MN; Wang-Gillam A; Trull L; Lockhart AC
Invest New Drugs; 2016 Feb; 34(1):84-95. PubMed ID: 26620496
[TBL] [Abstract][Full Text] [Related]
4. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.
Lin YG; Immaneni A; Merritt WM; Mangala LS; Kim SW; Shahzad MM; Tsang YT; Armaiz-Pena GN; Lu C; Kamat AA; Han LY; Spannuth WA; Nick AM; Landen CN; Wong KK; Gray MJ; Coleman RL; Bodurka DC; Brinkley WR; Sood AK
Clin Cancer Res; 2008 Sep; 14(17):5437-46. PubMed ID: 18765535
[TBL] [Abstract][Full Text] [Related]
5. Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.
Pan F; Tian J; Zhang X; Zhang Y; Pan Y
J Cancer Res Clin Oncol; 2011 Sep; 137(9):1397-408. PubMed ID: 21796416
[TBL] [Abstract][Full Text] [Related]
6. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
Freeman DJ; Bush T; Ogbagabriel S; Belmontes B; Juan T; Plewa C; Van G; Johnson C; Radinsky R
Mol Cancer Ther; 2009 Jun; 8(6):1536-46. PubMed ID: 19509246
[TBL] [Abstract][Full Text] [Related]
7. Concurrent and sequential administration of sunitinib malate and docetaxel in human non-small cell lung cancer cells and xenografts.
Wang D; Jiang Z; Zhang L
Med Oncol; 2012 Jun; 29(2):600-6. PubMed ID: 21455800
[TBL] [Abstract][Full Text] [Related]
8. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
Hirai H; Sootome H; Nakatsuru Y; Miyama K; Taguchi S; Tsujioka K; Ueno Y; Hatch H; Majumder PK; Pan BS; Kotani H
Mol Cancer Ther; 2010 Jul; 9(7):1956-67. PubMed ID: 20571069
[TBL] [Abstract][Full Text] [Related]
9. HSP90 inhibition enhances antimitotic drug-induced mitotic arrest and cell death in preclinical models of non-small cell lung cancer.
O'Connell BC; O'Callaghan K; Tillotson B; Douglas M; Hafeez N; West KA; Stern H; Ali JA; Changelian P; Fritz CC; Palombella VJ; McGovern K; Kutok JL
PLoS One; 2014; 9(12):e115228. PubMed ID: 25542032
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
[TBL] [Abstract][Full Text] [Related]
11. Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer.
Garon EB; Christofk HR; Hosmer W; Britten CD; Bahng A; Crabtree MJ; Hong CS; Kamranpour N; Pitts S; Kabbinavar F; Patel C; von Euw E; Black A; Michelakis ED; Dubinett SM; Slamon DJ
J Cancer Res Clin Oncol; 2014 Mar; 140(3):443-52. PubMed ID: 24442098
[TBL] [Abstract][Full Text] [Related]
12. A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma.
Shan W; Akinfenwa PY; Savannah KB; Kolomeyevskaya N; Laucirica R; Thomas DG; Odunsi K; Creighton CJ; Lev DC; Anderson ML
Clin Cancer Res; 2012 Jun; 18(12):3352-65. PubMed ID: 22535157
[TBL] [Abstract][Full Text] [Related]
13. Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma.
Qi W; Cooke LS; Liu X; Rimsza L; Roe DJ; Manziolli A; Persky DO; Miller TP; Mahadevan D
Biochem Pharmacol; 2011 Apr; 81(7):881-90. PubMed ID: 21291867
[TBL] [Abstract][Full Text] [Related]
14. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.
Qi W; Liu X; Cooke LS; Persky DO; Miller TP; Squires M; Mahadevan D
Int J Cancer; 2012 Jun; 130(12):2997-3005. PubMed ID: 21796626
[TBL] [Abstract][Full Text] [Related]
15. The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas.
Sehdev V; Katsha A; Ecsedy J; Zaika A; Belkhiri A; El-Rifai W
Cancer; 2013 Feb; 119(4):904-14. PubMed ID: 22972611
[TBL] [Abstract][Full Text] [Related]
16. Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.
Ceppi P; Papotti M; Monica V; Lo Iacono M; Saviozzi S; Pautasso M; Novello S; Mussino S; Bracco E; Volante M; Scagliotti GV
Mol Cancer Ther; 2009 Nov; 8(11):3066-74. PubMed ID: 19861409
[TBL] [Abstract][Full Text] [Related]
17. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.
Kretzner L; Scuto A; Dino PM; Kowolik CM; Wu J; Ventura P; Jove R; Forman SJ; Yen Y; Kirschbaum MH
Cancer Res; 2011 Jun; 71(11):3912-20. PubMed ID: 21502403
[TBL] [Abstract][Full Text] [Related]
18. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.
Hui EP; Lui VW; Wong CS; Ma BB; Lau CP; Cheung CS; Ho K; Cheng SH; Ng MH; Chan AT
Invest New Drugs; 2011 Dec; 29(6):1123-31. PubMed ID: 20467883
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo anti-tumour effects of MPT0B014, a novel derivative aroylquinoline, and in combination with erlotinib in human non-small-cell lung cancer cells.
Tsai AC; Pai HC; Wang CY; Liou JP; Teng CM; Wang JC; Pan SL
Br J Pharmacol; 2014 Jan; 171(1):122-33. PubMed ID: 24116948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
